Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL4360281 | 0.89 | EPHX2 (0.44) | EPHX2EPHX1LMNAHTTGAA | |
| SCHEMBL2210682 | 0.77 | GRIN2D (0.52) | EPHX2EPHX1LMNAGRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL7146424 | 0.75 | GRIN2D (0.50) | EPHX2EPHX1LMNAGRIN2DGRIN3B | |
| SCHEMBL7030977 | 0.73 | GRIN2D (0.44) | EPHX2EPHX1LMNAHTTGAA | |
| Acetic Acid SCHEMBL28387664 | 0.69 | THRB (0.46) | EPHX2EPHX1GAAALDH1A1 | |
| Amantadine SCHEMBL27677379 | 0.69 | THRB (0.68) | EPHX2EPHX1LMNAHTTGRIN2D | |
| SCHEMBL133014 | 0.67 | EPHX1 (0.68) | EPHX2EPHX1LMNAHTTGAA | |
| SCHEMBL19757636 | 0.67 | EPHX1 (0.68) | EPHX2EPHX1LMNAHTTGAA | |
| Acetic Acid SCHEMBL3328941 | 0.66 | THRB (0.41) | EPHX2EPHX1GAAALDH1A1 | |
| Acetic Acid SCHEMBL9166776 | 0.66 | THRB (0.41) | EPHX2EPHX1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802295-B1 | ORAL PHARMACEUTICAL COMPOSITION FOR TARGETED TRANSPORT OF A PLATINUM COMPLEX INTO THE COLORECTAL REGION, METHOD FOR PRODUCING AND USE AS MEDICAMENT THEREOF | PLIVA LACHEMA AS (CZ) | 2010-12-15 | — | — | EP | disclosed |
| EP-1809274-B1 | PHARMACEUTICAL COMPOSITION FOR RECTAL OR VAGINAL APPLICATION COMPRISING A PLATINUM COMPLEX | PLIVA LACHEMA AS (CZ) | 2010-04-28 | — | — | EP | disclosed |
| US-7655697-B2 | Oral pharmaceutical composition for targeted transport of a platinum complex into the colorectal region, method for producing and use as medicament thereof | PLIVA-LACHEMA A.S. (CZ) | 2010-02-02 | — | — | US | disclosed |
| US-20080008740-A1 | Pharmaceutical Composition for Rectal, or Vaginal Application, Method of Manufacturing and Use as Medicament Thereof | PLIVA-LACHEMA A.S. (CZ) | 2008-01-10 | — | — | US | disclosed |
| US-20070232819-A1 | Oral Pharmaceutical Composition for Targeted Transport of a Platinum Complex Into the Colorectal Region, Method for Producing and Use as Medicament Thereof | PLIVA-LACHEMA A.S. (CZ) | 2007-10-04 | — | — | US | disclosed |
| EP-1809274-A2 | PHARMACEUTICAL COMPOSITION FOR RECTAL OR VAGINAL APPLICATION COMPRISING A PLATINUM COMPLEX | Pliva-Lachema A.S. (CZ) | 2007-07-25 | — | — | EP | disclosed |
| EP-1802295-A1 | ORAL PHARMACEUTICAL COMPOSITION FOR TARGETED TRANSPORT OF A PLATINUM COMPLEX INTO THE COLORECTAL REGION, METHOD FOR PRODUCING AND USE AS MEDICAMENT THEREOF | Pliva-Lachema A.S. (CZ) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006029579-A1 | ORAL PHARMACEUTICAL COMPOSITION FOR TARGETED TRANSPORT OF A PLATINUM COMPLEX INTO THE COLORECTAL REGION, METHOD FOR PRODUCING AND USE AS MEDICAMENT THEREOF | PLIVA-LACHEMA A.S. (CZ) | 2006-03-23 | — | — | WO | disclosed |
| WO-2006026935-A2 | PHARMACEUTICAL COMPOSITION FOR RECTAL OR VAGINAL APPLICATION COMPRISING A PLATINUM COMPLEX | PLIVA-LACHEMA A.S. (CZ) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232819-A1 | Oral Pharmaceutical Composition for Targeted Transport of a Platinum Complex Into the Colorectal Region, Method for Producing and Use as Medicament Thereof | OSTC, SLCO4C1, OGFRL1 | EPHX2 4128/4885EPHX1 4599/4885LMNA 4622/4885 |
| US-20080008740-A1 | Pharmaceutical Composition for Rectal, or Vaginal Application, Method of Manufacturing and Use as Medicament Thereof | AGL, GK, ACR | EPHX2 1823/4885EPHX1 2526/4885LMNA 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.